D
Citius Pharmaceuticals, Inc. CTXR
$1.35 -$0.01-0.51% NASDAQ
Recommendation
Prev Close
$1.58
Volume
193,023
Avg Vol (90D)
892,112
Market Cap
$29.19M
Dividend & Yield
--
52-Week Range
$0.65 - $12.84
P/E (TTM)
--
EPS (TTM)
-$5.08
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven?
10/28/2025 - Simply Wall St
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6. ...
10/21/2025 - GuruFocus
Citius Pharmaceuticals Secures $6M in Stock Offering
10/21/2025 - TipRanks Financial Blog
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
10/21/2025 - PR Newswire
Citius Pharmaceuticals Announces a Registered Direct Offering of $6. ...
10/21/2025 - GuruFocus
Citius Pharmaceuticals announces $6M registered direct offering priced ATM
10/21/2025 - The Fly
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
10/21/2025 - PR Newswire
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR Commercial Launch
10/20/2025 - PR Newswire
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
10/17/2025 - GuruFocus
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
10/17/2025 - PR Newswire
Citius Oncology signs exclusive commercialization agreement with EVERSANA
10/16/2025 - TipRanks Financial Blog
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR
10/16/2025 - PR Newswire
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Large Increase in Short Interest
9/20/2025 - Ticker Report
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
9/10/2025 - PR Newswire
Citius Oncology Raises $9 Mln Through Direct Offering And Private Placement
9/9/2025 - Nasdaq News: Markets
Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
9/9/2025 - PR Newswire
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch
8/22/2025 - PR Newswire
Citius Posts Wider Loss in Fiscal Q3
8/13/2025 - Fool.com Headlines
Citius Pharmaceuticals (CTXR): Analyst Maintains 'Buy' Rating CTXR Stock News
8/13/2025 - GuruFocus
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides ...
8/12/2025 - GuruFocus
Citius Pharmaceuticals Inc (CTXR) Q3 Earnings: EPS of ($0. ...
8/12/2025 - GuruFocus
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides ...
8/12/2025 - GuruFocus
Citius Pharmaceuticals reports Q3 EPS (8c) vs.(7c) last year
8/12/2025 - TipRanks Financial Blog
Citius Pharmaceuticals reports Q3 EPS (8c) vs.(7c) last year
8/12/2025 - The Fly
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
8/12/2025 - PR Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$41.14M
EBIT (TTM)
-$41.14M
Net Income (TTM)
-$40.26M
Balance Sheet
Total Assets (Q)
$127.68M
Total Debt (Q)
$1.88M
Total Liabilities (Q)
$60.12M
Book Value Per Share (Q)
$4.49
Cash Flow
Cash from Operations (TTM)
-$20.58M
Cash from Investing (TTM)
-$5.00M
Cash from Financing (TTM)
$13.76M
Net Change in Cash (TTM)
-$11.82M
Filings
Filing Date
Tuesday, August 12, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Dec 22 and 26 (est)
Price History
Loading...
Beta
1.36
7-Day Total Return
-21.33%
30-Day Total Return
16.65%
60-Day Total Return
10.01%
90-Day Total Return
1.74%
Year to Date Total Return
-65.13%
1-Year Total Return
-84.92%
2-Year Total Return
-92.97%
3-Year Total Return
-94.94%
5-Year Total Return
-94.52%
52-week Low
May 08, 2025 - $0.65
52-week High
Nov 12, 2024 - $12.84
Valuation
Market Cap
$29.19M - Nano Cap
Enterprise Value
$27.48M
Price/Sales (TTM)
--
Price/Book (Q)
0.35
Dividends and Shares
Shares Outstanding
11.01
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
citiuspharma.com
Phone Number
908 967 6677
Address
11 Commerce Drive
Cranford, NJ 07016
Country
United States
Year Founded
2007
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted... more
NASDAQ 11/05/2025 2:44PM Eastern Quotes delayed